CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion LLC, a pharmaceutical company developing T-type calcium channel (Cav3) inhibitors for the treatment of oncologic and neurologic diseases, announced today that research collaborators from the University of Virginia, The Johns Hopkins University and Adult Brain Tumor Consortium, and Yale University will present data corroborating the use of Cavion’s novel cancer drug mibefradil as a brain cancer therapy at the Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) being held in San Antonio, Texas, November 19-22.
